Clinical Communications
A case of aquagenic urticaria successfully treated with omalizumab

https://doi.org/10.1016/j.jaip.2015.12.017Get rights and content

References (9)

There are more references available in the full text version of this article.

Cited by (20)

  • Clinical and diagnostic features of 33 patients with aquagenic urticaria

    2023, Journal of Allergy and Clinical Immunology: In Practice
  • A Systematic Review of Aquagenic Urticaria—Subgroups and Treatment Options

    2022, Journal of Allergy and Clinical Immunology: In Practice
    Citation Excerpt :

    The combination of 1stAH1 (cyproheptadine) with sertraline and methscopolamine bromide patch was used in 1 patient and led to complete control.51 In 2 cases who did not respond to the combination of 1stAH1 and 2ndAH1, omalizumab (300 mg every 4 weeks) was used in 1 patient and led to complete control after 2 injections.55 Stanozolol was applied in another patient with human immunodeficiency virus infection and reported complete control; however, his symptoms relapsed after discontinuation of stanozolol.2

  • Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence

    2018, Journal of Allergy and Clinical Immunology
    Citation Excerpt :

    The advanced search option was used with the terms “omalizumab” AND, for example, “cold urticaria” to encompass results from all fields. This was complemented by any additional published or in press evidence known to us at the time of publication (Table II).19,20,36-76 All publications have been included, regardless of whether the results were positive or negative, to present a fair and unbiased account of the available published evidence.

  • Management of chronic inducible urticaria according to the guidelines: A prospective controlled study

    2017, Journal of Dermatological Science
    Citation Excerpt :

    In 2014, omalizumab was approved by the FDA for AH-refractory CSU patients [39,40] and it was recommended by JTFPP, EAACI/GA2LEN/EDF/WAO and BSACI guidelines due to its efficacy and safety [5,8,9]. Efficacy of omalizumab for CSU has been shown by placebo controlled clinical trials [39,40–45], while there are just case reports and case series in the literature for CIndU [11,17,46–50]. There are on-going trials evaluating the efficacy of omalizumab in different types of CIndU which have not been published yet [CUTEX (NCT01580592), UFO (NCT02169115), XOLUS (NCT02262130), CUN-OMAL-UCOL (NCT02012387)].

View all citing articles on Scopus

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

View full text